Approval · Notice of Compliance 25262 · 2021
ILARIS: Notice of Compliance 25262
Issued February 22, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25262
- Date
- February 22, 2021
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Expansion of Still¿s disease indication to include : Active Still¿s disease, and adult-onset Still¿s disease (AOSD)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ILARIS | Not yet assigned | — |
Medicinal ingredients
- CANAKINUMAB 150 MG per ML